Janus Henderson Investors ISIN LU1897414568

Janus Henderson Horizon Biotechnology Fund

Janus Henderson Horizon Biotechnology Fund is an active equity fund from Janus Henderson Investors, ISIN LU1897414568.

  • Active
  • Equity
  • Global
  • Fund size (GBP) £1.5B

The Fund aims to provide capital growth over the long term. Performance target: To outperform the NASDAQ Biotechnology Total Return Index by 2% per annum, before the deduction of charges, over any 5 year period.

How the fund has returned, and where it ranks among peers. Returns to Sep 2026 end, GBP net total return.
+46.1% Q1
1 year return
+85.2% Q1
3 year return
+105.0% Q1
5 year return
Daily NAV, percent change from the start of the range. Source: FE fundinfo.
  • 1 month −5.8%
  • 3 months −6.2%
  • Volatility, 3 years 25.8%
  • Ongoing charge (OCF)
  • Fund size (GBP) £1.5B

What the fund holds

Where the money is: sectors, countries and largest holdings. As supplied by FE fundinfo, last updated 6 Oct 2026. Swipe or use the arrows for more panels.

By sector

Spot concentrations at a glance. Share of the fund's portfolio, as supplied by FE fundinfo, last updated 6 Oct 2026.
Biotechnology/Medical87.2%
Pharmaceuticals12.1%
Healthcare & Medical Products0.0%
See all sectorsA free account shows the full list.

By country

Spot concentrations at a glance. Share of the fund's portfolio, as supplied by FE fundinfo, last updated 6 Oct 2026.
US86.6%
BE4.6%
DK3.0%
See all countriesA free account shows the full list.

By asset class

Spot concentrations at a glance. Share of the fund's portfolio, as supplied by FE fundinfo, last updated 6 Oct 2026.
US Equities87.2%
Belgian Equities4.2%
Danish Equities2.9%
See all asset classesA free account shows the full list.

Largest holdings

The biggest positions, and how concentrated the fund is. As supplied by FE fundinfo, last updated 6 Oct 2026.
  1. 1. REVOLUTION MEDICINES, INC.5.9%
  2. 2. PRAXIS PRECISION MEDICINES4.7%
  3. 3. BRIDGEBIO PHARMA, INC.4.0%
  4. 4. ARGENX SE3.9%
  5. 5. GILEAD SCIENCES, INC.3.9%
See all holdingsA free account shows the full list.

Macro events and this fund

Recent events linked to this fund by its country and sector exposure, and how it moved after. A measured move, not a cause.

Performance, risk and facts

Judge return, risk and cost before a client conversation. Relative return uses the chart's time range. Facts as reported by the manager.

Against its benchmark

How the fund compares with its benchmark over the same period.

Risk

How bumpy the ride has been, plus the regulatory risk rating.
Volatility, 3 years25.8%
Scale 0 to 40%
Sharpe ratio, 3 years (FE)1.07
Scale −1 to 3
Largest fall from a peak (maximum drawdown), 3 years
−35.1%
Alpha, 3 years (FE)
17.52
Beta, 3 years (FE)
1.51

Volatility and maximum drawdown: calculated by Funds Benchmark, as at 30 Sep 2026.

Sharpe, alpha, beta: FE fundinfo, as at 6 Jul 2026.

Fund facts

Legal and cost facts for a client note. As reported by the manager.
ISIN
LU1897414568
Fund manager
Acker, Lyons, Mohedas
Management company
Janus Henderson Investors Europe S.A.
Depositary
BNP Paribas Luxembourg Branch
Benchmark
NASDAQ Biotechnology Total Return Index
Ongoing charge
Share class launch date
10 Dec 2018
Domicile
LU
Fund type
open-ended fund
SRRI
6 of 7

What a sum would have become

What an amount would have grown to over the period.
n/a

Past performance is not a reliable guide to future returns. Capital is at risk. Source: FE fundinfo. Returns are GBP net total return to month end unless stated. Headline returns to Sep 2026. Fund size is shown in GBP.

Managed by Janus Henderson Investors

View every Janus Henderson Investors fund on Funds Benchmark →

Other FE GL Equity Health Care funds

Sector: FE GL Equity Health Care

View the FE GL Equity Health Care sector overview — top funds, average performance, exposure →

Top country exposure